Generation of a Severe Hemophilia A Humanized Mouse Model Capable of Inducing an Anti-FVIII Immune Response
Thrombosis and Haemostasis · 01.05.2025 · 125 (05) · 435-446
DOI: 10.1055/a-2518-7157 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.05.2025. Verfasst von Akihisa Oda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII, Antibodies, Neutralizing. Die Arbeit nennt 45 Literaturangaben.
Abstract (Originalsprache)
Factor VIII (FVIII) replacement therapy induces anti-FVIII neutralizing antibodies in approximately 30% of patients with severe hemophilia A (HA). Owing to the lack of experimental systems that allow for the study of human anti-FVIII immune responses, the mechanisms underlying replacement therapy-induced anti-FVIII antibodies in HA patients remain largely unknown. Therefore, experimental systems that enable the study of human anti-FVIII immune responses are needed. We generated severe immunodeficient NOD-scid IL-2Rnull; FVIIInull mice (NOG HA) that can serve as hosts for human cord blood (hCB) transplantation and established a HA mouse with a humanized immune system to induce the anti-FVIII responses in human immune cells in vivo. The proportions of immune cell subsets (CD8+ T cells, CD4+ T cells, CD19+ B cells, CD33+ macrophages, and CD56+ natural killer (NK) cells) in the bone marrow, spleen, and peripheral blood were similar between NOG HA and NOG mice 4 months after hCB transplantation. The hCB-engrafted NOG HA mice retained HA severity. To activate the anti-FVIII immune response in hCB-engrafted NOG HA mice, we administered recombinant (r)FVIII plus lipopolysaccharide (LPS) once a week for 3 months. We detected both anti-FVIII IgM and IgG in the plasma of hCB-engrafted NOG HA mice after treatment with 12 doses of rFVIII and LPS. Taken together, our humanized mice with HA maintained a severe phenotype and generated human anti-FVIII IgG antibodies in vivo, thus representing a valuable model for studying human anti-FVIII immune responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.
- Department of Immunology, Nara Medical University, Kashihara, Nara, Japan.
- Central Institute for Experimental Animals, Kawasaki, Kanagawa, Japan.
- Advanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Nara, Japan.
- The Course of Thrombosis and Hemostasis Molecular Pathology, Nara Medical University, Kashihara, Nara, Japan.
- Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Nara, Japan.
ORCID-Profile: Naruto Shimonishi
Zitieren
APA
Oda, A., Furukawa, S., Kitabatake, M., Ouji-Sageshima, N., Ito, T., Takahashi, R., Kawamura, T., Nakajima, Y., Shimonishi, N., Ogiwara, K., Shima, M., & Nogami, K. (2025). Generation of a Severe Hemophilia A Humanized Mouse Model Capable of Inducing an Anti-FVIII Immune Response. Thrombosis and Haemostasis, 125(05), 435-446. https://doi.org/10.1055/a-2518-7157
Vancouver
Oda A, Furukawa S, Kitabatake M, Ouji-Sageshima N, Ito T, Takahashi R, et al. Generation of a Severe Hemophilia A Humanized Mouse Model Capable of Inducing an Anti-FVIII Immune Response. Thrombosis and Haemostasis. 2025;125(05):435-446. doi:10.1055/a-2518-7157
BibTeX
@article{Oda2025,
author = {Oda, Akihisa and Furukawa, Shoko and Kitabatake, Masahiro and Ouji-Sageshima, Noriko and Ito, Toshihiro and Takahashi, Riichi and Kawamura, Takeshi and Nakajima, Yuto and Shimonishi, Naruto and Ogiwara, Kenichi and Shima, Midori and Nogami, Keiji},
title = {Generation of a Severe Hemophilia A Humanized Mouse Model Capable of Inducing an Anti-FVIII Immune Response},
journal = {Thrombosis and Haemostasis},
year = {2025},
volume = {125},
number = {05},
pages = {435--446},
doi = {10.1055/a-2518-7157}
}
EUVIMED